The results of a recent national research led by the internal medicine service of the Juan Ramón Jiménez University Hospital confirm that hyperglycemia is a strong and important risk factor in COVID-19 non-critical hospitalized patients, regardless of the background of diabetes andwhich is associated with greater need for mechanical ventilation, admission to ICU and risk of death in COVID-19 context.
Thus it follows from the results of said research, linked to the Semi-Covid-19 Clinical Registry of the Spanish Society of Internal Medicine (SEMI), which have just been published in Annals of Medicine, in a scientific article that sign 25 specialists in MedicineInternal under the title “Admission HyperglycemiaSa A Predictor of Mortality in Patients Hospitalized with Covid-19 Rensass of Diabetes Status: Data from the Spanish semi-covid-19 recorded”.
The study has been coordinated by Dr. Javier Carrasco, specialist in Internal Medicine at the Juan Ramón Jiménez University Hospital and the doctors Francisco Javier Martínez and Alicia Hidalgo participated, together with a dozen specialists of internal medicine, infectious diseases and pneumology of theHospital Center.
Thus, hyperglycemia in the initial phases of the disease behaves as a predictor of clinical poor evolution both in patients with diabetes and without it, since it favors the cell invasion of the virus at the beginning of the disease.In addition, COVID-19 is associated with new cases of diabetes, to decompensation of previous diabetes and the metabolic stress generated by hyperglycemia.
Therefore, the researchers conclude that "the detection of hyperglycemia in patients without pre-existing diabetes and the early treatment of the same should be mandatory in the management of hospitalized patients with hospitalized COVID-19" and that "admission hyperglycemia should not be passed throughAlto, regardless of the history of diabetes, since it constitutes a strong predictor of mortality to the entrance, regardless of the history of diabetes ”.
The main objective of this multicenter and retrospective study has been to evaluate the association between blood glucose levels (GS) and hospital mortality in non-critical patients hospitalized with COVID-19 in Spain.
To do this, clinical data of 11,312 hospitalized patients were evaluated, qualifying for three groups, according to blood glucose levels-free glucose concentration in the blood-at hospital admission: less than 140 mg/dl, 140-180 mg/dl andgreater than 180 mg/dl.The main assessment criteria was hospital mortality for all causes.
According to study findings, accumulated probability of mortality was significantly higher in patients with hyperglycemia compared to patients with normal blood glucose, regardless of pre -existing diabetes.Of the 11,312 patients, only 2,128 (18.9%) had diabetes and 2,289 (20.4%) died during hospitalization.Hospital mortality rates were 15.7% for glycemia patients under 140 mg/dl, 33.7% for those with 140-180 mg/dl and 41.1% for patients with more than 180 mg/DL of blood glucose.
Therefore, hyperglycemia - after adjusting parameters by age, diabetes, hypertension and other confusion factors - was an independent risk factor of mortality and, in addition, it was also associated with a requirement of mechanical ventilation, Entry into ICU and mortality.
This research is part of the more than 70 on the semi-Covid-19 record, which contains data from more than 17,000 patients with SARS-COV-2 infection confirmed and who were treated by internist doctors, medical specialists in the front lineDuring pandemia.In this registry, almost 900 participateInternal doctors of 214 hospitals from all over the country.
